An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) will release its third quarter 2021 financial results on November 12, 2021. The management will host a conference call at 8 a.m. ET to discuss the results and provide a business update. Investors can participate by calling (833) 301-1146 in the U.S. or (914) 987-7386 internationally, using Conference ID 6662686. A live webcast will be available on the company’s website.
Forma focuses on developing therapeutics for rare hematologic diseases and cancers, emphasizing innovation to meet high unmet medical needs.
Positive
Upcoming release of third quarter 2021 financial results is scheduled for November 12, 2021.
Management's conference call will provide insights into the company's financial status and future outlook.
Negative
None.
WATERTOWN, Mass.--(BUSINESS WIRE)--
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release third quarter 2021 financial results Friday, Nov. 12, 2021. Forma management will host an investment community conference call at 8 a.m. Eastern Time, on Nov. 12, 2021 to discuss these financial results and provide a business update.
Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 6662686. A live webcast of the conference call will be available in the “News & Investors” section of Forma’s website at www.formatherapeutics.com.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.
